Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease. At the ...

With an infrastructure in place to market its lone commercial product Ruconest, it made sense in 2019 for Pharming Group to scoop up another rare disease candidate in the same arena. Four years later, ...

Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta ...

6 analysts have expressed a variety of opinions on Pharming (NASDAQ:PHAR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...

When we look around, we are amazed at the speed with which the world is changing. Online fraud techniques such as Pharming and other cybercrime attacks are at an all-time high. To overcome such ...

A pharming attack tries to redirect a website’s traffic to a fake website controlled by the attacker, usually for the purpose of collecting sensitive information from victims or installing malware on ...

First came phishing scams, in which con artists hooked unwary internet users one by one into compromising their personal data. Now the latest cyberswindle, pharming, threatens to reel in entire ...